|Day Low/High||12.59 / 13.44|
|52 Wk Low/High||6.40 / 15.82|
Some of your predictions were spot on, others not so much.
This group of contestants have nearly perfect records picking FDA and European drug approvals.
Ziopharm, AP Pharma and Biogen Idec will headline a very big week of approval decisions, Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg.
Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.
Who will be the premier prognosticator of FDA drug approvals in 2013?
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies
Look at A.P. Pharma as a trade, not as a long-term investment, says trader Mark Messier.
The biotech bull market has created a new category of swing trade catalysts.